MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

MDT

95.62

+0.1%↑

VEEV

286.22

-0.26%↓

A

138.32

+1.29%↑

HQY

93.32

+3.04%↑

PHR.US

22.18

-0.63%↓

Search

Arrowhead Pharmaceuticals Inc

Closed

SectorHealthcare

36.3 2.8

Overview

Share price change

24h

Current

Min

35.31

Max

37.01

Key metrics

By Trading Economics

Income

-547M

-179M

Sales

-515M

28M

Profit margin

-643.397

Employees

609

EBITDA

-563M

-166M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+0.96% upside

Dividends

By Dow Jones

Next Earnings

25 Nov 2025

Market Stats

By TradingEconomics

Market Cap

2.9B

5.2B

Previous open

33.5

Previous close

36.3

News Sentiment

By Acuity

72%

28%

344 / 371 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

Arrowhead Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

12 Oct 2025, 21:50 UTC

Acquisitions, Mergers, Takeovers

Caterpillar to Acquire Australia's RPM Global for $730 Million

10 Oct 2025, 21:38 UTC

Acquisitions, Mergers, Takeovers

Strathcona Resources Terminates Take-Over Bid for MEG Energy

12 Oct 2025, 23:47 UTC

Market Talk

Gold Rises, Buoyed by Monetary Debasement Fears -- Market Talk

12 Oct 2025, 23:39 UTC

Market Talk

Oil Rises on Likely Technical Recovery, Mildly Positive Sentiment -- Market Talk

12 Oct 2025, 23:22 UTC

Market Talk

New Zealand Braces For Renewed Trade War Uncertainty -- Market Talk

12 Oct 2025, 23:16 UTC

Acquisitions, Mergers, Takeovers

Caterpillar Inc. Enters Into Agreement To Acquire RPMGlobal >CAT RUL.AU

12 Oct 2025, 22:32 UTC

Market Talk

Copper, U.S. Thermal Coal Stand Out as Metals Ride Macro Tailwinds -- Market Talk

12 Oct 2025, 21:28 UTC

Acquisitions, Mergers, Takeovers

RPM Global Says Board Unanimously Recommends Shareholders Accept Caterpillar Offer

12 Oct 2025, 21:28 UTC

Acquisitions, Mergers, Takeovers

RPM Global Agrees to Takeover by Caterpillar

12 Oct 2025, 21:28 UTC

Acquisitions, Mergers, Takeovers

RPM Global Says Caterpillar Offering A$5.00/Share in Cash

11 Oct 2025, 08:20 UTC

Market Talk

Financial Services Roundup: Market Talk

11 Oct 2025, 00:18 UTC

Acquisitions, Mergers, Takeovers

Why Biotech May Be Back -- Barrons.com

10 Oct 2025, 21:07 UTC

Earnings
Acquisitions, Mergers, Takeovers

Dell Is Just Beginning to Tell Its AI Story. Buy the Stock. -- Barrons.com

10 Oct 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

10 Oct 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

10 Oct 2025, 20:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

10 Oct 2025, 20:06 UTC

Market Talk

Fed Won't Publish Monthly Industrial Data Next Week -- Market Talk

10 Oct 2025, 20:06 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

10 Oct 2025, 19:56 UTC

Market Talk

U.S.-China Tension Weighs Down on Treasury Yields, Dollar -- Market Talk

10 Oct 2025, 19:20 UTC

Market Talk

Oil Futures Sink As Trump Rekindles Trade Tensions -- Market Talk

10 Oct 2025, 19:02 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Loss -- Market Talk

10 Oct 2025, 18:58 UTC

Market Talk

Canada's Jobs Gain Marks a 'Head Fake' For Economy -- Market Talk

10 Oct 2025, 18:52 UTC

Market Talk

PepsiCo Lays Groundwork for Improvement -- Market Talk

10 Oct 2025, 18:47 UTC

Market Talk

Precious Metals Turn Higher After Profit-Taking Slide -- Market Talk

10 Oct 2025, 18:35 UTC

Market Talk

Canada's Next Rate Cut May be Pushed to December -- Market Talk

10 Oct 2025, 18:31 UTC

Market Talk

Canada's Labor Market Firming. But Conditions Vary Across Country -- Market Talk

10 Oct 2025, 17:32 UTC

Market Talk

U.S. Oil Rig Count Declines by Four to 418 -- Market Talk

10 Oct 2025, 16:55 UTC

Earnings

These Stocks Are Moving the Most Today: MP Materials, Nvidia, Alibaba, Venture Global, Applied Digital, Qualcomm, and More -- Barrons.com

10 Oct 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

10 Oct 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

Peer Comparison

Price change

Arrowhead Pharmaceuticals Inc Forecast

Price Target

By TipRanks

0.96% upside

12 Months Forecast

Average 35.75 USD  0.96%

High 80 USD

Low 12 USD

Based on 11 Wall Street analysts offering 12 month price targets forArrowhead Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

11 ratings

6

Buy

5

Hold

0

Sell

Technical Score

By Trading Central

11.5 / 12.23Support & Resistance

Short Term

Weak Bearish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

344 / 371 Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.
help-icon Live chat